Fountain Healthcare Partners
Fountain Healthcare Partners is a venture fund that provides risk capital and expertise to ambitious entrepreneurs building outstanding life sciences companies. The firm focuses on a limited number of active portfolio companies to provide more than just capital, offering strategic guidance and support. With a strong presence in both Europe and the United States, Fountain Healthcare Partners invests primarily in the life sciences sector, including specialty pharma, biopharmaceuticals, medical devices, and diagnostics. The firm is committed to responsible investment and aims to facilitate partnerships and build international networks to help its portfolio companies succeed.
Fountain Healthcare Partners
Two Docklands Central, Level 4, Guild Street, IFSC, Dublin, D01 K2C5, Ireland
What We Do
Fountain Healthcare Partners provides strategic guidance and support to its portfolio companies, helping them grow smartly, mitigate risk, and expand their impact.
Investment Range
Portfolio
MMI is dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions through its Symani Surgical System.
#Robotics
Mainstay Medical focuses on commercializing its innovative implantable Restorative Neurostimulation system, ReActiv8, for people with disabling mechanical CLBP.
#Medical Devices
XyloCor is developing novel gene therapies for cardiovascular disease, with its lead product candidate XC001 in clinical development for refractory angina.
#Biopharmaceuticals
Cappella develops solutions for the treatment of complex coronary artery disease, specifically bifurcation vascular disease, with its Sideguard™ Sidebranch stent.
#Medical Devices
Opsona focuses on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, with its lead product OPN-305 targeting inflammatory diseases.
#Biotechnology
Genable Technologies is developing a suppression/replacement gene therapy technology for Retinitis Pigmentosa, with its lead product GT038.
#Biotechnology
Civitas is developing transformative therapeutics using the ARCUSTM respiratory delivery platform, with a focus on Parkinson’s disease.
#Pharmaceuticals